Yasuhiro Yoshimatsu

Yasuhiro Yoshimatsu

Auto-generated profile, based on publicly available information

Yasuhiro Yoshimatsu

Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University 3 Department of Cellular Physiological Chemistry Tokyo, Japan

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2003 in Cell
Verified
Journal Article
Closed access
QZQinghong Zhang
Qinghong Zhang
YYYasuhiro Yoshimatsu
Yasuhiro Yoshimatsu
JHJeffrey Hildebrand
Jeffrey Hildebrand
SFSteven M Frisch
Steven M Frisch
RGRichard H Goodman
Richard H Goodman

9 May 2020 in Cancer Science
Verified
Journal Article
Open access
PDF file
YYYasuhiro Yoshimatsu
Yasuhiro Yoshimatsu
IWIkumi Wakabayashi
Ikumi Wakabayashi
SKShiori Kimuro
Shiori Kimuro
NTNaoya Takahashi
Naoya Takahashi
KTKazuki Takahashi
Kazuki Takahashi
TWTetsuro Watabe
Tetsuro Watabe
The tumor microenvironment (TME) consists of various components including cancer cells, tumor vessels, cancer‐associated fibroblasts (CAFs), and inflammatory cells. These components interact with each other via various cytokines, which often induce tumor progression. Thus, a greater understanding of TME networks is crucial for the development of novel cancer therapies. Many cancer types express high levels of TGF‐β, which induces endothelial‐to‐mesenchymal transition (EndMT), leading to formation of CAFs. Although we previously reported that CAFs derived from EndMT promoted tumor formation, the molecular mechanisms underlying these interactions remain to be elucidated. Furthermore, tumor‐infiltrating inflammatory cells secrete various cytokines, including TNF‐α. However, the role of TNF‐α in TGF‐β‐induced EndMT has not been fully elucidated. Therefore, this study examined the effect of TNF‐α on TGF‐β‐induced EndMT in human endothelial cells (ECs). Various types of human ECs underwent EndMT in response to TGF‐β and TNF‐α, which was accompanied by increased and decreased expression of mesenchymal cell and EC markers, respectively. In addition, treatment of ECs with TGF‐β and TNF‐α exhibited sustained activation of Smad2/3 signals, which was presumably induced by elevated expression of TGF‐β type I receptor, TGF‐β2, activin A, and integrin αv, suggesting that TNF‐α enhanced TGF‐β‐induced EndMT by augmenting TGF‐β family signals. Furthermore, oral squamous cell carcinoma‐derived cells underwent epithelial‐to‐mesenchymal transition (EMT) in response to humoral factors produced by TGF‐β and TNF‐α‐cultured ECs. This EndMT‐driven EMT was blocked by inhibiting the action of TGF‐βs. Collectively, our findings suggest that TNF‐α enhances TGF‐β‐dependent EndMT, which contributes to tumor progression.

1 September 2006 in Developmental Cell
Verified
Journal Article
Closed access
GHGangwen Han
Gangwen Han
ALAllen G. Li
Allen G. Li
YLYao-Yun Liang
Yao-Yun Liang
POPhilip Owens
Philip Owens
WHWei He
Wei He
XWXiao-Jing Wang
Xiao-Jing Wang

24 February 2009 in Genes to Cells
Verified
Journal Article
Closed access
PDF file
TYTomoko Yamazaki
Tomoko Yamazaki
YYYasuhiro Yoshimatsu
Yasuhiro Yoshimatsu
YMYasuyuki Morishita
Yasuyuki Morishita
KMKohei Miyazono
Kohei Miyazono
TWTetsuro Watabe
Tetsuro Watabe

1 January 2011 in International Journal of Inflammation
Verified
Journal Article
Open access
PDF file
YYYasuhiro Yoshimatsu
Yasuhiro Yoshimatsu
TWTetsuro Watabe
Tetsuro Watabe
Most cardiac diseases caused by inflammation are associated with fibrosis in the heart. Fibrosis is characterized by the accumulation of fibroblasts and excess deposition of extracellular matrix (ECM), which results in the distorted organ architecture and function. Recent studies revealed that cardiac fibroblasts are heterogeneous with multiple origins. Endothelial-mesenchymal transition (EndMT) plays important roles in the formation of cardiac fibroblasts during pathological settings. EndMT is regulated by signaling pathways mediated by cytokines including transforming growth factor (TGF)-β. Better understanding of the mechanisms of the formation of cardiac fibroblasts via EndMT may provide an opportunity to develop therapeutic strategies to cure heart diseases.

7 February 2022 in Inflammation and Regeneration
Verified
Journal Article
Open access
PDF file
YYYasuhiro Yoshimatsu
Yasuhiro Yoshimatsu
TWTetsuro Watabe
Tetsuro Watabe
Endothelial–mesenchymal transition (EndoMT), a cellular differentiation process in which endothelial cells (ECs) lose their properties and differentiate into mesenchymal cells, has been observed not only during development but also in various pathological states in adults, including cancer progression and organ/tissue fibrosis. Transforming growth factor-β (TGF-β), an inflammation-related cytokine, has been shown to play central roles in the induction of EndoMT. TGF-β induces EndoMT by regulating the expression of various transcription factors, signaling molecules, and cellular components that confer ECs with mesenchymal characteristics. However, TGF-β by itself is not necessarily sufficient to induce EndoMT to promote the progression of EndoMT-related diseases to a refractory extent. In addition to TGF-β, additional activation by other inflammatory factors is often required to stabilize the progression of EndoMT. Since recent lines of evidence indicate that inflammatory signaling molecules act as enhancers of EndoMT, we summarize the roles of inflammatory factors in the induction of EndoMT and related diseases. We hope that this review will help to develop therapeutic strategies for EndoMT-related diseases by targeting inflammation-mediated EndoMT.